Cord Blood News Volume 3.45 | Nov 17 2011

Human MAIT and CD8αα Cells Develop from a Pool of Type-17 Pre-Committed CD8⁺ T Cells
By transcriptional and functional analyses researchers demonstrate that a pool of polyclonal, pre-committed type-17 CD161++CD8αβ+ T-cells exists in cord blood, from which a prominent mucosal associated invariant T (MAIT) cell (TCR Vα7.2+) population emerges post-natally. [Blood] Abstract

HLA-Matched Sibling Stem Cell Transplantation in Children with β-Thalassemia with Anti-Thymocyte Globulin as Part of the Preparative Regimen: The Greek Experience
This study retrospectively analyzed the outcome of 75 consecutive pediatric patients with β-thalassemia who underwent HLA-matched sibling transplantation after anti-thymocyte globulin-containing myeloablative conditioning regimens. [Bone Marrow Transplant] Abstract

Significance of Increased Blastic-Appearing Cells in Bone Marrow following Myeloablative Unrelated Cord Blood Transplantation in Adult Patients
This study aimed to analyze the incidence, chronology, biological features, and clinical significance of an increased number of non-leukemic blastic-appearing lymphocytes in a series of 165 consecutive adult patients showing myeloid engraftment after myeloablative unrelated cord blood transplant in a single institution. [Biol Blood Marrow Transplant] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Patients with Treatment-Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Results suggest that the strategy of induction with high-dose cytarabine therapy followed by allogeneic stem cell transplantation improves the overall outcome for patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. [Biol Blood Marrow Transplant] Abstract

Relationship of Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic Syndromes
Researchers analyzed the association between race/ethnicity and outcomes of unrelated single umbilical cord blood transplantation for leukemia and myelodysplastic syndromes. [Biol Blood Marrow Transplant] Abstract

Compatibility of Different Polymers for Cord Blood-Derived Hematopoietic Progenitor Cells
Here researchers evaluate the capacity of several two-dimensional polymers to support hematopoietic progenitor cells proliferation. [J Mater Sci Mater Med] Abstract

Improvement in Cardiac Function following Transplantation of Human Umbilical Cord Matrix-Derived Mesenchymal Cells
Researchers examined whether human umbilical cord mesenchymal cells may contribute to heart regeneration following an acute experimental myocardial infarction. [Cardiology] Abstract

Donor Cell-Derived Acute Myeloid Leukemia after Second Allogenic Cord Blood Transplantation in a Patient with Fanconi Anemia
In this case study, researchers present a young boy diagnosed with Fanconi anemia who underwent an umbilical cord blood transplantation. [Pediatr Transplant] Abstract

FDA Approves First Cord Blood Product
The U.S. Food and Drug Administration approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy. [U.S. Food and Drug Administration] Press Release

Cord Blood America Announces Fourth Major Supplier Agreement with Tissue Bank
Cord Blood America, Inc. announced that it has signed its fourth Supplier Agreement with a well-respected, accredited, tissue bank for which it will provide placenta collection services for research and transplantation use by the tissue bank. [Cord Blood America, Inc.] Press Release

Cord Blood America Revenues Up 59 Percent; Gross Profit Up 91 Percent
Cord Blood America, Inc. announced revenues for the nine months ended September 30, 2011 totaled $4.38 million, up 59 percent compared to revenues of $2.75 million in the same period in 2010. [Cord Blood America, Inc.] Press Release

Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer
University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells from the dose limiting toxicity of chemotherapy with Temodar. [University Hospitals] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page  to see a complete list of events in the cord blood community.

Lab Technologist – Tissue Culture (STEMCELL Technologies) 

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Laboratory Technician – Cord Blood Processing (Perkin Elmer)

Laboratory Supervisor – Cellular Therapy (NewYork-Presbyterian Hospital)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.